Zheng H, Katsurada K, Liu X, Knuepfer MM, Patel KP
Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist
2 In the SURMOUNT-1 trial, 25.9% of tirzepatide participants experienced nausea, and 4.37.1% discontinued due to adverse events (depending on dose)
Tirzepatide works by activating GLP-1 and GIP receptors in the brain and digestive system, signaling fullness and reducing appetite
[32] By measuring changes in the antral area, two-dimensional ultrasonography can provide information about gastric emptying, and complete gastric emptying is determined when the antral area returns to its preprandial baseline
Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts